Share on StockTwits

Equities research analysts at ISI Group started coverage on shares of Valeant Pharmaceuticals Intl (NYSE:VRX) in a research note issued to investors on Thursday, reports. The firm set a “buy” rating on the stock.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded down 1.44% on Thursday, hitting $117.32. 1,508,458 shares of the company’s stock traded hands. Valeant Pharmaceuticals Intl has a 52-week low of $98.61 and a 52-week high of $153.10. The stock’s 50-day moving average is $116.6 and its 200-day moving average is $127.. The company’s market cap is $39.350 billion. Valeant Pharmaceuticals Intl also was the target of a large decrease in short interest in the month of August. As of August 15th, there was short interest totalling 13,138,567 shares, a decrease of 27.1% from the July 31st total of 18,029,591 shares. Currently, 4.0% of the shares of the company are short sold. Based on an average trading volume of 3,685,996 shares, the short-interest ratio is currently 3.6 days.

Valeant Pharmaceuticals Intl (NYSE:VRX) last announced its earnings results on Thursday, July 31st. The company reported $1.91 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $1.91. The company had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the company posted $1.34 earnings per share. The company’s quarterly revenue was up 86.2% on a year-over-year basis. On average, analysts predict that Valeant Pharmaceuticals Intl will post $7.99 earnings per share for the current fiscal year.

Several other analysts have also recently commented on the stock. Analysts at Zacks downgraded shares of Valeant Pharmaceuticals Intl from an “outperform” rating to an “underperform” rating in a research note on Wednesday, August 6th. They now have a $101.00 price target on the stock. Separately, analysts at Susquehanna cut their price target on shares of Valeant Pharmaceuticals Intl to $160.00 in a research note on Friday, August 1st. Finally, analysts at Piper Jaffray cut their price target on shares of Valeant Pharmaceuticals Intl from $151.00 to $135.00 in a research note on Friday, August 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $148.00.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

The Fly On The Wall

Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.